Immunovant, Inc. (IMVT) SEC Filings & Earnings Calls

Clinical Development Risk

“We cannot provide any assurance that we will submit an IND, NDA, CTA or other similar application for regulatory approval for our product candidates within projected timeframes or whether any such application will be accepted for review or ultimately approved by the relevant regulatory authorities.” · word for word

Financing Risk

“Our current funds will not be sufficient to enable us to complete all necessary development and, if approved, commercially launch IMVT-1402 in all indications we are currently evaluating.” · word for word

Reliance on Single Product Candidate

“Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor ("FcRn")” · word for word

No revenue; net loss increasing; reliance on clinical success.

“Net loss $153.2M vs $120.6M prior year; no product revenue.”

Clinical trial failure risk

“Because the first development milestone was not achieved, the portion of the PSUs that was eligible to vest on March 31, 2026 was forfeited.” · word for word

Controlling shareholder risk

“Roivant Sciences Ltd. (1) 113,327,007 54.9%” · word for word

Cash burn risk

“Net Loss (in 000s): 2026 $(505,606).”

Batoclimab discontinued after Phase 3 TED trials failed; $39M contractual costs recognized in Q4.

“We announced topline results from the two Phase 3 clinical studies evaluating batoclimab for adults with active, moderate-to-severe thyroid eye disease (TED), neither of which met the primary endpoint. Following these results, we discontinued further development of batoclimab across all indications.” · word for word

HanAll license dispute risk

“We have commenced discussions with HanAll regarding the potential return to HanAll of certain rights for batoclimab. ... This could result in a dispute with HanAll that may result in arbitration or litigation.” · word for word

Clinical trial execution risk

“Clinical trials are very expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes.” · word for word

No revenue and ongoing losses

“We have not generated any revenues to date and do not anticipate generating any revenues unless and until it successfully completes development and obtains regulatory approval for IMVT-1402, batoclimab or any future product candidate.”

Clinical trial failure risk; no approved products; reliance on pipeline.

“Clinical-stage company with no approved products; all value depends on trial outcomes.”

Dilution risk from large equity issuance

“26.2 million shares issued at $21.00 per share”

Potential arbitration or litigation with HanAll over batoclimab rights

“This could result in a dispute with HanAll that may result in arbitration or litigation” · word for word

Clinical trial risks; first top-line data for registrational studies not expected until 2027

“Except for D2T RA, the first top-line data for any of the potentially registrational studies is not expected until sometime in calendar year 2027” · word for word

R&D leadership restructuring may impact clinical development pipeline.

“CMO departure as part of restructuring of R&D leadership structure.”

Batoclimab TED studies readout delayed to H1 2026; competitive dynamics may impact market positioning.

“due to evolving competitive dynamics, the Company anticipates sharing topline results from both TED studies concurrently in the first half of calendar year 2026” · word for word

Clinical-stage company with no approved products; significant R&D spend and net losses.

“Net loss was $126.5 million for Q2; R&D expenses $114.2 million”

Clinical trial failure risk

“We expect to report top-line results from these trials in 2027.” · word for word

Macroeconomic uncertainty

“Unfavorable conditions in the economy in the U.S., Canada and abroad may negatively affect the growth of our business and our results of operations.” · word for word